SCHEMBL5136941

SCHEMBL5136941

CCCCN(Cc1ccc(C(=O)OC)cc1)Cc1c(C(C)(C)C)nc(-c2ccccc2)n1CCCC.CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(OC(C)=O)cc1)CC1CCCCC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 4/20 0.35
C5AR1 P21730 1/20 0.34
GNRHR P30968 2/20 0.33
PPARG P37231 2/20 0.33
PPARA Q07869 2/20 0.33
LPAR1 Q92633 1/20 0.33
LPAR5 Q9H1C0 1/20 0.33
AGTR1 P30556 1/20 0.33
ACHE P22303 2/20 0.32
HDAC1 Q13547 2/20 0.32
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
KMT2A Q03164 1/20 0.32
MGAM O43451 1/20 0.32
GAA P10253 1/20 0.32
SI P14410 1/20 0.32
MGAM2 Q2M2H8 1/20 0.32
AVPR1B P47901 1/20 0.32
FNTA P49354 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL650668 0.84 AGTR1 (0.38) BCHEC5AR1AGTR1HDAC1MEN1
SCHEMBL5135950 0.81 LPAR1 (0.42) C5AR1PPARGPPARALPAR1LPAR5
SCHEMBL5137681 0.80 PTGES (0.44) C5AR1LPAR1LPAR5HDAC1ALDH1A1
SCHEMBL5137352 0.80 TLR7 (0.42) C5AR1AVPR1B
SCHEMBL5137557 0.79 C5AR1 (0.42) BCHEC5AR1MEN1ALDH1A1LMNA
SCHEMBL648135 0.79 CRHR1 (0.44) PPARGPPARALPAR1LPAR5AGTR1
SCHEMBL5136734 0.78 LTB4R2 (0.40) C5AR1PPARGPPARAHDAC1
SCHEMBL5135054 0.78 C5AR1 (0.40) C5AR1LPAR1LPAR5HDAC1
SCHEMBL5136197 0.78 C5AR1 (0.40) BCHEC5AR1ALDH1A1AVPR1B
SCHEMBL5137594 0.78 C5AR1 (0.42) C5AR1PPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed